Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Continues Looking For The “Right” Biotech Buying Opportunity

This article was originally published in The Pink Sheet Daily

Executive Summary

Speaking at a Goldman Sachs investor conference, CEO Clark discusses Merck’s plans in biotech.

You may also be interested in...



Merck’s Clark: 2009 is a Year of Fundamental Change

In 2009, Merck is implementing a new business model that fundamentally transforms the company and is crucial to its future, CEO Richard Clark told analysts at a Goldman Sachs health care conference Jan. 7

Merck Announces Major FOB Initiative With Its New Business Unit

Merck BioVentures plans to launch follow-on version of Amgen’s Aranesp by 2012.

Can Big Pharma Save Biotech Investors?

Want to know how bad off small biotechs are these days? Investment bankers are so desperate to unload companies, they've taken to calling on corporate development departments with lists of "wounded animals" - those companies with just a few months of cash remaining, according to a business development head at a big pharmaceutical company

Related Content

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel